Goodwin advised Alpha Wave Global on the investment. Alpha Wave Global, alongside Mubadala Capital, invested in Aman Group’s $360 million funding round. The investment values Aman, run...
Aman’s $360 Million Funding Round
Nimbus Therapeutics’ $210 Million Private Financing
Goodwin advised Nimbus Therapeutics on the financing. Nimbus Therapeutics announced its $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Crown LNG’s Business Combination with Catcha Investment Corp.
Nelson Mullins served as legal counsel to Crown, and Goodwin served as legal counsel to Catcha Investment Corp. Crown LNG Holdings AS and Catcha Investment Corp...
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
Eli Lilly’s $1.925 Billion Acquisition of Versanis Bio
Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
Evelo Biosciences’ $25.5 Million Private Placement
Goodwin advised Flagship Pioneering on the investment. Evelo Biosciences, Inc. (Nasdaq:EVLO) announced a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of...
ReNAgade Therapeutics’ $300 Million Series A Financing Round
Goodwin advised ReNAgade Therapeutics on the fundraising. ReNAgade Therapeutics announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has...
ElevateBio’s $401 Million Series D Financing Round
Goodwin advised ElevateBio on the financing. ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
Quest Diagnostics’ Acquisition of Haystack Oncology
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
Avadel Pharmaceuticals’ $75 Million Royalty Financing
Goodwin Procter advised Avadel Pharmaceutics on the deal. Avadel announced its royalty agreement with RTW Investments, LP and certain of its affiliates for up to $75 million....